Effect of Tissue Plasminogen Activator on Treatment Outcome and Neuronal Degeneration in Acute Ischemic Stroke
Background: Acute ischemic stroke [AIS] is a leading worldwide neurological morbidity with significant disability. Recombinant tissue plasminogen activator [r-TPA] is approved for the treatment of AIS.Neuron-specific enolase [NSE] is a marker of brain damage in patients with traumatic brain injury,...
Guardado en:
Autores principales: | Muhammad Masoud, Shimaa Abd Elkareem, Somia Sayed, Hatem Elmasry |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Al-Azhar University, Faculty of Medicine (Damietta)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8cfc97cf4f54f2da6df80f51ad39a4e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
por: Iannetta D, et al.
Publicado: (2021) -
Trombolisis intravenosa en accidente cerebro vascular isquémico agudo en un hospital público de Chile: Análisis prospectivo de 54 casos
por: Guevara O,Carlos, et al.
Publicado: (2016) -
Individualized Prediction Of Stroke-Associated Pneumonia For Patients With Acute Ischemic Stroke
por: Huang GQ, et al.
Publicado: (2019) -
Reduced Vitamin D Levels are Associated with Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke
por: Huang GQ, et al.
Publicado: (2019) -
Capturing Intravenous Thrombolysis for Acute Stroke at the <italic toggle="yes">ICD‐9</italic> to <italic toggle="yes">ICD‐10</italic> Transition: Case Volume Discontinuity in the United States National Inpatient Sample
por: Lily W. Zhou, et al.
Publicado: (2021)